News and Trends 7 Feb 2023
Endogena Therapeutics retinitis pigmentosa treatment gets FDA fast track designation
The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a fast track development program. Fast track…